Current events, press releases and news | Le Lézard
Le Lézard gathers news regarding technologies, sciences, business, health, environment, travelling, sports, leisure activities, transportation and more.
Actualités, communiqués de presse et nouvelles | Le Lézard
Le Lézard regroupe des nouvelles traitant des technologies, sciences, affaires, santé, environnement, voyage, sport, loisir, du transport et plus encore.
Gilead and Terray Therapeutics Announce Multi-Target Research ...
21 小时之前 · Gilead Sciences, Inc. and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across ...
Health Canada Approves XEOMIN® (incobotulinumtoxinA) for …
22 小时之前 · Merz Therapeutics, a business of Merz Group and a leader in the field of neurotoxins, today announced that Health Canada approved XEOMIN® (incobotulinumtoxinA) for the treatment of post-stroke ...
Longest Follow-Up Data Reported for Kite's Tecartus® CAR T-Cell …
2024年12月9日 · Kite, a Gilead Company , announced results today from four analyses that continue to demonstrate the durability of response of Tecartus® (brexucabtagene autoleucel) in patients with relapsed ...
Kite's Yescarta® Only CAR T-Cell Therapy to Show Durable …
2024年12月9日 · Kite, a Gilead Company , today announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta® (axicabtagene ciloleucel) in patients with relapsed/refractory non ...
GNT Pharma Reports Significant Improvements in Stroke Patients …
6 天之前 · GNT Pharma Co. Ltd, a late-stage pharmaceutical company founded in 1998 with offices in Seoul Korea, Italy and USA, announced today the results of its latest Phase II ('SONIC') and Phase ...
European Commission Approves BeiGene's TEVIMBRA for First …
2024年11月27日 · BeiGene, Ltd. , a global oncology company that intends to change its name to BeOne Medicines, today announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination ...
LIB Therapeutics Announce Positive Results from Lerodalcibep 72 …
2024年11月18日 · LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company advancing Lerodalcibep, a novel, third-generation PCSK9 inhibitor announced positive results from two sub ...
UCB presents latest scientific research in epilepsy at American ...
2024年11月26日 · Dr Dimitrios Bourikas, Global Medical Head of Epilepsy, UCB, commented: "We are excited to share our latest epilepsy research during the American Epilepsy Society Annual Meeting.It's an honor to ...